12.37 pc CAGR projected in sales of medicines
Friday, 29 October 2010
FE Report
Sales of prescription and OTC medicines in the country would be more than treble to $3.74 billion by 2019 at a rate of 12.37 per cent CAGR, a report by Business Monitor International (BMI) said.
"Sales of prescription drugs and over-the-counter (OTC) medicines are expected to grow from Tk 79.74 billion ($1.16 billion) in 2009 to Tk 268.42 billion ($3.74 billion) in 2019, representing a compound annual growth rate (CAGR) of 12.37 per cent", said the report of BMI, a leading and independent provider of proprietary data, analysis, ratings, rankings and forecasts covering 175 countries and 22 industrial sectors.
According to the BMI's Pharmaceuticals & Healthcare Business Environment Ratings, Bangladesh moves down one place to occupy 15th position in the fourth-quarter 2010 update of the table.
This adjustment now sees Bangladesh placed above Pakistan and Cambodia, the latter being judged the least attractive proposition for investment by multinational pharmaceutical companies, said the report.
It said, Bangladesh's pharmaceutical rating is 39.7, a figure that has changed marginally from the previous quarter.
Sales of prescription and OTC medicines in the country would be more than treble to $3.74 billion by 2019 at a rate of 12.37 per cent CAGR, a report by Business Monitor International (BMI) said.
"Sales of prescription drugs and over-the-counter (OTC) medicines are expected to grow from Tk 79.74 billion ($1.16 billion) in 2009 to Tk 268.42 billion ($3.74 billion) in 2019, representing a compound annual growth rate (CAGR) of 12.37 per cent", said the report of BMI, a leading and independent provider of proprietary data, analysis, ratings, rankings and forecasts covering 175 countries and 22 industrial sectors.
According to the BMI's Pharmaceuticals & Healthcare Business Environment Ratings, Bangladesh moves down one place to occupy 15th position in the fourth-quarter 2010 update of the table.
This adjustment now sees Bangladesh placed above Pakistan and Cambodia, the latter being judged the least attractive proposition for investment by multinational pharmaceutical companies, said the report.
It said, Bangladesh's pharmaceutical rating is 39.7, a figure that has changed marginally from the previous quarter.